Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
70.42 USD | -2.06% | -0.97% | +6.49% |
Apr. 23 | MetLife Increases Quarterly Dividend to $0.545 Per Share From $0.52, Payable June 11 to Shareholders of Record on May 7 | MT |
Apr. 23 | MetLife Raises Quarterly Dividend by 4.8% | DJ |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Its low valuation, with P/E ratio at 8.71 and 7.73 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company has a low valuation given the cash flows generated by its activity.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- One of the major weak points of the company is its financial situation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Life & Health Insurance
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+6.49% | 51.99B | B+ | ||
+1.35% | 48.18B | B | ||
+9.53% | 41.99B | B+ | ||
+6.55% | 39.96B | B+ | ||
+19.34% | 37.85B | B | ||
+2.84% | 29.82B | B | ||
-7.77% | 27.37B | B- | ||
-18.42% | 24.45B | A- | ||
+6.89% | 21.84B | A | ||
+20.69% | 21.14B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MET Stock
- Ratings MetLife, Inc.